Grace Therapeutics, Inc.
GTx-104
aneurysmal subarachnoid hemorrhage (aSAH)
Resolved
75days ago
Catalyst readout · Apr 23, 2026
What's at stake
A key catalyst for GTx-104 (aneurysmal subarachnoid hemorrhage (aSAH)) is expected Apr 23, 2026.
Primary source
· SEC 8-K
verified 16h ago
“The Company intends to request a Type A meeting with the FDA to clarify the path forward and determine the appropriate next steps.”